Trial Profile
A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (Ponatinib) in Routine Clinical Practice in the United States (OMNI).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms OMNI
- Sponsors ARIAD Pharmaceuticals; Takeda Pharma
- 30 Oct 2020 Status changed from recruiting to discontinued.
- 22 Mar 2019 Planned End Date changed from 30 Sep 2021 to 30 Sep 2020.
- 22 Mar 2019 Planned primary completion date changed from 30 Sep 2021 to 30 Sep 2020.